Study Summary
Evaluation the safety and efficacy of cord blood-derived CAR-T cells in patients with relapsed/refractory B cell leukemia/lymphoma whose disease relapsed after autologous CAR-T cells therapy or who fail to preparation for autologous CAR-T cells
Want to learn more about this trial?
Request More InfoInterventions
CAR-T cellsBIOLOGICAL
collecting cord blood for CAR-T cells culture; three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CAR-T cell with a dose of 0.5-3x106/kg
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Henan Cancer Hospital | Zhengzhou | Henan | China |
| Henan Cancer Hospital | Zhengzhou | Henan | China |